Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.

Literature DB >> 19903681

Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.

Mark W Brunvand, Mitchell Bitter.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2009 PMID： 19903681 PMCID： PMC2833087 DOI： 10.3324/haematol.2009.013102

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

11 in total

1. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors: Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal: Blood Date: 2004-01-22 Impact factor: 22.113

Review 2. Molecular mechanisms of amyloidosis.

Authors: Giampaolo Merlini; Vittorio Bellotti
Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245

Review 3. Transplantation for amyloidosis.

Authors: Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji Kumar
Journal: Curr Opin Oncol Date: 2007-03 Impact factor: 3.645

4. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Authors: Vaishali Sanchorawala; Martha Skinner; Karen Quillen; Kathleen T Finn; Gheorghe Doros; David C Seldin
Journal: Blood Date: 2007-08-02 Impact factor: 22.113

5. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.

Authors: P Moreau; V Leblond; P Bourquelot; T Facon; A Huynh; D Caillot; O Hermine; M Attal; M Hamidou; G Nedellec; A Ferrant; B Audhuy; R Bataille; N Milpied; J L Harousseau
Journal: Br J Haematol Date: 1998-06 Impact factor: 6.998

Review 6. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.

Authors: Raymond L Comenzo
Journal: Contrib Nephrol Date: 2007 Impact factor: 1.580

Review 7. Bortezomib in the front-line treatment of multiple myeloma.

Authors: Paul G Richardson; Constantine Mitsiades; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth C Anderson
Journal: Expert Rev Anticancer Ther Date: 2008-07 Impact factor: 4.512

8. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors: Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal: Br J Haematol Date: 2003-07 Impact factor: 6.998